Figure 3. CXCL1 promotes glycolysis in patients with CRC.
CXCL1 expression was silenced by shRNA in HCT116 and RKO cell lines, and the knockdown efficacy was determined by Western blotting (A) and RT-PCR (B). Knockdown of CXCL1 expression significantly decreased glucose consumption (C), lactate production (D), and ATP production (E). (F) Patients with high CXCL1 expression exhibited higher SUVmax than those with low CXCL1 expression (P=0.001). (G and H) Silencing CXCL1 expression decreased GLUT1, HK2, and LDHA mRNA expression in HCT116 (G) and RKO (H) cell; *P<0.05.